Skip to main content

Thais Cuadros Arasa

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Thais Cuadros Arasa

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Projects

Modulation of age-dependent neuromelanin accumulation as a novel therapeutic strategy for Parkinson’s disease and brain aging

IP: Miquel Vila Bover
Collaborators: Ariadna Laguna Tuset, Thais Cuadros Arasa, Marta González Sepúlveda, Annabelle Parent
Funding agency: Fundació "La Caixa"
Funding: 466004
Reference: FBLC/HR17-00513/VILA
Duration: 01/09/2018 - 05/01/2022

La disfunción autofágica/lisosomal en la enfermedad de Parkinson: caracterización y desarrollo de nuevas estrategias traslacionales con el lisosoma como diana terapéutica

IP: Marta Martínez Vicente
Collaborators: Jorge Hernández Vara, Oriol de Fabregues-Boixar Nebot, Thais Cuadros Arasa, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Manuel Quintana Luque
Funding agency: Instituto de Salud Carlos III
Funding: 99220
Reference: PI17/00496
Duration: 01/01/2018 - 30/06/2021

Rol de la neuromelanina en la enfermedad de Parkinson y del envejecimiento cerebral: estudio `ptemcoañ terpéutico en nuevos modelos preclínicos "humanizados" in vivo.

IP: Miquel Vila Bover
Collaborators: Ariadna Laguna Tuset, Thais Cuadros Arasa
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 363000
Reference: SAF2016-77541-R
Duration: 30/12/2016 - 29/12/2020

Apoptosi i Neurodegeneració (GRC)

IP: -
Collaborators: Marta Martínez Vicente, Miquel Vila Bover, Joaquin Lopez Soriano, Mercè Boada Rovira, Jordi Bove Badell, Thais Cuadros Arasa
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 30000
Reference: 2014 SGR 1609
Duration: 01/01/2014 - 31/12/2016

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Elisabet Miro Casas

Elisabet Miro Casas

Research technician
Cardiovascular Diseases
Read more
Edurne Ruiz Marti

Edurne Ruiz Marti

Infectious Diseases
Read more
Ariadna Campos Martorell

Ariadna Campos Martorell

Growth and Development
Read more
Marta Aguayo Álvarez

Marta Aguayo Álvarez

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.